share_log

While Institutions Invested in Omeros Corporation (NASDAQ:OMER) Benefited From Last Week's 54% Gain, Retail Investors Stood to Gain the Most

While Institutions Invested in Omeros Corporation (NASDAQ:OMER) Benefited From Last Week's 54% Gain, Retail Investors Stood to Gain the Most

雖然機構投資了奧麥羅製藥公司(納斯達克:OMER),受益於上週54%的漲幅,零售投資者將獲益最多
Simply Wall St ·  11/15 18:13

Key Insights

主要見解

  • Significant control over Omeros by retail investors implies that the general public has more power to influence management and governance-related decisions
  • A total of 25 investors have a majority stake in the company with 44% ownership
  • Institutions own 43% of Omeros
  • 散戶投資者對奧麥羅製藥的顯著控制意味着公衆在影響管理和治理相關決策方面擁有更大的權力。
  • 共有25名投資者擁有該公司的多數股份,佔股44%。
  • 機構持有奧麥羅製藥43%的股份。

To get a sense of who is truly in control of Omeros Corporation (NASDAQ:OMER), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 53% to be precise, is retail investors. Put another way, the group faces the maximum upside potential (or downside risk).

要了解誰真正控制着奧麥羅製藥公司(納斯達克:OMER),了解該業務的所有權結構是很重要的。持有該公司最多股份的團體,大約佔53%,是散戶投資者。換句話說,該團體面臨着最大上行潛力(或下行風險)。

Following a 54% increase in the stock price last week, retail investors profited the most, but institutions who own 43% stock also stood to gain from the increase.

在上週股票價格上漲54%後,零售投資者利潤最多,但持有43%股票的機構也從中獲利。

In the chart below, we zoom in on the different ownership groups of Omeros.

在下面的圖表中,我們仔細查看奧麥羅製藥的不同持股群體。

big
NasdaqGM:OMER Ownership Breakdown November 15th 2024
納斯達克GM:OMER 持股分佈 2024年11月15日

What Does The Institutional Ownership Tell Us About Omeros?

機構持股告訴我們關於奧麥羅製藥什麼?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

We can see that Omeros does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Omeros, (below). Of course, keep in mind that there are other factors to consider, too.

我們可以看到奧麥羅製藥確實有機構投資者,他們持有公司股票的一部分。這表明該公司在投資社區中有一定程度的可信度。然而,最好小心依賴於機構投資者所帶來的所謂驗證。機構投資者也是會犯錯誤的。如果兩家大型機構投資者同時試圖拋售同一股票,股票價格大幅下跌並不罕見。因此,查看奧麥羅製藥過去的盈利軌跡是值得的(見下文)。當然,還要記住其他因素也很重要。

big
NasdaqGM:OMER Earnings and Revenue Growth November 15th 2024
納斯達克GM:奧麥羅製藥2024年11月15日的盈利和營業收入增長

We note that hedge funds don't have a meaningful investment in Omeros. Looking at our data, we can see that the largest shareholder is Ingalls & Snyder, LLC with 7.9% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.1% and 5.6%, of the shares outstanding, respectively. Additionally, the company's CEO Gregory Demopulos directly holds 3.5% of the total shares outstanding.

我們注意到對奧麥羅製藥的對沖基金沒有進行有意義的投資。根據我們的數據,最大的股東是Ingalls & Snyder, LLC,持有7.9%的流通股份。同時,第二大和第三大股東分別持有7.1%和5.6%的流通股份。此外,該公司的CEO Gregory Demopulos直接持有3.5%的總流通股份。

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

對我們的所有權數據進行更深入的研究表明,前25名股東的持股總額不到註冊表的一半,表明有一個小股東的大群體,其中沒有單個股東擁有多數股份。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

研究機構所有權是衡量和篩選股票預期表現的好方法。研究分析師的看法也可以達到同樣的效果。股票的分析師覆蓋率很低,但不多。因此,可以有更多的空間來增加其覆蓋範圍。

Insider Ownership Of Omeros

奧麥羅製藥的內部持股情況

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

雖然內部人員的具體定義可能是主觀的,但幾乎所有人都認爲董事會成員是內部人員。公司管理層應向董事會回答問題,後者應代表股東的利益。值得注意的是,有時高層管理人員也會成爲董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。

Our most recent data indicates that insiders own some shares in Omeros Corporation. It has a market capitalization of just US$243m, and insiders have US$11m worth of shares, in their own names. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

我們最新的數據表明,內部人持有奧麥羅製藥的一些股票。其市值僅爲24300萬美元,內部人名下的股票價值爲1100萬美元。有些人會說這表明股東與董事會之間的利益一致。但值得檢查一下這些內部人是否有在賣出股票。

General Public Ownership

一般大衆所有權

The general public -- including retail investors -- own 53% of Omeros. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

公衆,包括散戶投資者,擁有奧麥羅製藥53%的股份。這種規模的持股賦予了公衆投資者一定的集體權力。他們可以並且很可能會影響高管薪酬、分紅政策和擬議的業務收購決策。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand Omeros better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 5 warning signs for Omeros (of which 4 are concerning!) you should know about.

始終值得考慮不同的股東群體。但要更好地理解奧麥羅製藥,我們需要考慮許多其他因素。比如風險。每家公司都存在風險,我們發現了奧麥羅製藥的5個警告信號(其中4個令人擔憂!)你應該知道。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但最終,決定該業務所有者將獲得多大利益的是未來而非過去。因此,我們認爲最好查看此免費報告,以了解分析師是否預測更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論